Trial · NCT00706589

Aripiprazole in Children and Adolescents With Chronic Tic Disorder or Tourette's Disorder

NCT00706589, Phase 3, Completed, Korea Otsuka Pharmaceutical Co., Ltd.; results first posted 2013-07-26

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Aripiprazole in Children and Adolescents With Chronic Tic Disorder or Tourette's Disorder. Trials, record NCT00706589. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00706589

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Aripiprazole in Children and Adolescents With Chronic Tic Disorder or Tourette's Disorder
NCT number: NCT00706589
Status: Completed
Phases: Phase 3
Enrollment: 61 participants, actual
Lead sponsor: Korea Otsuka Pharmaceutical Co., Ltd.
Conditions: Chronic Motor or Vocal Tic Disorder, Tourette's Disorder
Interventions: aripiprazole, placebo
First posted: 2008-06-27
Last updated: 2013-07-26
Results first posted: 2013-07-26

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Mean Change of Total Tic Scores in K-YGTSS From Randomization (Baseline, Visit 2) to the Final Visit (Visit 7)	10 week	The meaning of the total tic scores is a sum of the total motor tic score and total phonic tic score and the total tic score will be indicated from zero point to 50 points. And also, for the global tic severity scale is sum of the total tic scores and impairment score and it will be indicated from zero point to 100 points. Additionally, for the imparment score is also indicated from zero to 50 points same as total tic scores. And it is divided as 0 point, 10 point, 20 point and etc… Lastly, someone who gets a high score, it will be considered worse result.
Secondary	1)Percent Change of Total Tic Scores on the Korean Version of YaleGlobalTicseverity Scale.2)Response Rate Assessed With the Tic Score ClinicalGlobalImpressionImprovementScale.3)Mean Change in Scores on the Tic Score ClinicalGlobal ImpressionSeverityScale.	10 weeks

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
SECONDARY	1)Percent Change of Total Tic Scores on the Korean Version of YaleGlobalTicseverity Scale.2)Response Rate Assessed With the Tic Score ClinicalGlobalImpressionImprovementScale.3)Mean Change in Scores on the Tic Score ClinicalGlobal ImpressionSeverityScale.	10 weeks		participants	MEAN
PRIMARY	Mean Change of Total Tic Scores in K-YGTSS From Randomization (Baseline, Visit 2) to the Final Visit (Visit 7)	10 week	ITT (Intention-To-Treat)analysis	units on a scale	MEAN

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Mean Change of Total Tic Scores in K-YGTSS From Randomization (Baseline, Visit 2) to the Final Visit (Visit 7)	Aripiprazole		-9.62	Full Range -32 to 8	units on a scale
Mean Change of Total Tic Scores in K-YGTSS From Randomization (Baseline, Visit 2) to the Final Visit (Visit 7)	Placebo		-14.97	Full Range -33 to 2	units on a scale

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Aripiprazole	32
Overall Study	STARTED	Placebo	29
Overall Study	COMPLETED	Aripiprazole	29
Overall Study	COMPLETED	Placebo	25
Overall Study	NOT COMPLETED	Aripiprazole	3
Overall Study	NOT COMPLETED	Placebo	4

Source ClinicalTrials.gov

Adverse events34

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Sedation	Nervous system disorders	Aripiprazole	4	32	5
other	Sedation	Nervous system disorders	Placebo	3	28	5
other	Akathisia	Nervous system disorders	Aripiprazole	2	32	2
other	Akathisia	Nervous system disorders	Placebo	4	28	5
other	Headache	Nervous system disorders	Aripiprazole	5	32	5
other	Headache	Nervous system disorders	Placebo	1	28	1
other	Dizziness	Nervous system disorders	Aripiprazole	1	32	1
other	Dizziness	Nervous system disorders	Placebo	4	28	4
other	Extrapyramidal disorder	Nervous system disorders	Aripiprazole	3	32	3
other	Extrapyramidal disorder	Nervous system disorders	Placebo	2	28	2

1 to 10 of 34Source ClinicalTrials.gov

See all 34 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Aripiprazole
Total, all-cause mortality	Placebo
Total, other adverse events	Aripiprazole	24	32
Total, other adverse events	Placebo	20	28
Total, serious adverse events	Aripiprazole	0	32
Total, serious adverse events	Placebo	0	28

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
24021518	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Aripiprazole vs Placebo: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00706589

GET https://conductscience.org/api/trials/v1/NCT00706589/events?page=2

API reference For AI assistants